People · Operator
Named in public records as an officer, director or promoter · active 2012–2023 · Pharmaceuticals, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| VYNE Therapeutics Inc. | — | Pharmaceuticals | Series C | $139.5M | $971.1M | 2022 |
| Viveve Medical, Inc. | — | Biotechnology | Series A | $41.5M | $12.3M | 2020 |
| Carbylan Therapeutics, Inc. | — | Other Health Care | Series A | $15.0M | $80.7M | 2012 |
Steven Basta at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steven Basta on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Albert L. Cha | 2 | 2 |
| Steven L. Basta | 2 | 2 |
| Andrew Perlman | 1 | 15 |
| Albert Cha | 1 | 9 |
| Chris Ehrlich | 1 | 6 |
| Brigitte Smith | 1 | 5 |
| Arlene Morris | 1 | 5 |
| Guy Nohra | 1 | 5 |
| Anthony Bruno | 1 | 4 |
| Edward Schnipper | 1 | 4 |
| Carl Simpson | 1 | 4 |
| Mark Weeks | 1 | 4 |
| Guy P. Nohra | 1 | 3 |
| James Atkinson | 1 | 3 |
| Keith A. Katkin | 1 | 3 |
| Daniel Janney | 1 | 3 |
| James Larrick | 1 | 2 |
| Mark Colella | 1 | 2 |
| Ketan L. Patel | 1 | 2 |
| Gregory W. Mann | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.